annual EBITDA:
-$8.71M-$4.48M(-106.01%)Summary
- As of today (September 12, 2025), AKBA annual EBITDA is -$8.71 million, with the most recent change of -$4.48 million (-106.01%) on December 31, 2024.
- During the last 3 years, AKBA annual EBITDA has risen by +$219.66 million (+96.19%).
- AKBA annual EBITDA is now -106.01% below its all-time high of -$4.23 million, reached on December 31, 2023.
Performance
AKBA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$14.40M+$577.00K(+4.17%)Summary
- As of today (September 12, 2025), AKBA quarterly EBITDA is $14.40 million, with the most recent change of +$577.00 thousand (+4.17%) on June 1, 2025.
- Over the past year, AKBA quarterly EBITDA has increased by +$13.72 million (+2002.92%).
- AKBA quarterly EBITDA is now -74.90% below its all-time high of $57.39 million, reached on June 30, 2022.
Performance
AKBA quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$24.34M+$13.72M(+129.21%)Summary
- As of today (September 12, 2025), AKBA TTM EBITDA is $24.34 million, with the most recent change of +$13.72 million (+129.21%) on June 1, 2025.
- Over the past year, AKBA TTM EBITDA has increased by +$21.84 million (+873.52%).
- AKBA TTM EBITDA is now at all-time high.
Performance
AKBA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AKBA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -106.0% | +2002.9% | +873.5% |
| 3 y3 years | +96.2% | -74.9% | +127.5% |
| 5 y5 years | +96.5% | +129.6% | +110.6% |
AKBA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -106.0% | +96.2% | -74.9% | +135.3% | at high | +127.2% |
| 5 y | 5-year | -106.0% | +96.5% | -74.9% | +118.5% | at high | +109.5% |
| alltime | all time | -106.0% | +96.5% | -74.9% | +116.3% | at high | +109.5% |
AKBA EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $14.40M(+4.2%) | $24.34M(+129.2%) |
| Mar 2025 | - | $13.83M(-1909.9%) | $10.62M(-221.9%) |
| Dec 2024 | -$8.71M(+106.0%) | -$764.00K(-75.6%) | -$8.71M(-408.0%) |
| Sep 2024 | - | -$3.13M(-557.1%) | $2.83M(+13.2%) |
| Jun 2024 | - | $685.00K(-112.4%) | $2.50M(+42.4%) |
| Mar 2024 | - | -$5.50M(-151.1%) | $1.76M(-119.9%) |
| Dec 2023 | -$4.23M(-85.7%) | $10.78M(-411.5%) | -$8.82M(-55.7%) |
| Sep 2023 | - | -$3.46M(+5764.4%) | -$19.90M(-65.2%) |
| Jun 2023 | - | -$59.00K(-99.6%) | -$57.24M(<-9900.0%) |
| Mar 2023 | - | -$16.08M(+5351.5%) | $214.00K(-100.6%) |
| Dec 2022 | -$29.57M(-87.1%) | -$295.00K(-99.3%) | -$33.33M(-62.7%) |
| Sep 2022 | - | -$40.80M(-171.1%) | -$89.34M(+1.1%) |
| Jun 2022 | - | $57.39M(-215.7%) | -$88.39M(-59.1%) |
| Mar 2022 | - | -$49.62M(-11.9%) | -$216.09M(-2.8%) |
| Dec 2021 | -$228.37M(+0.5%) | -$56.31M(+41.3%) | -$222.37M(-8.8%) |
| Sep 2021 | - | -$39.85M(-43.3%) | -$243.74M(-4.6%) |
| Jun 2021 | - | -$70.30M(+25.8%) | -$255.36M(+9.3%) |
| Mar 2021 | - | -$55.91M(-28.0%) | -$233.73M(+2.8%) |
| Dec 2020 | -$227.32M(-9.0%) | -$77.68M(+50.9%) | -$227.32M(-3.4%) |
| Sep 2020 | - | -$51.48M(+5.8%) | -$235.41M(+2.3%) |
| Jun 2020 | - | -$48.67M(-1.7%) | -$230.14M(-0.5%) |
| Mar 2020 | - | -$49.50M(-42.3%) | -$231.29M(-6.8%) |
| Dec 2019 | -$249.87M(+63.7%) | -$85.76M(+85.6%) | -$248.22M(-1.1%) |
| Sep 2019 | - | -$46.20M(-7.3%) | -$250.90M(+8.0%) |
| Jun 2019 | - | -$49.82M(-25.0%) | -$232.31M(+6.6%) |
| Mar 2019 | - | -$66.43M(-24.9%) | -$217.95M(+24.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$152.65M(+100.7%) | -$88.44M(+220.2%) | -$175.82M(+142.3%) |
| Sep 2018 | - | -$27.62M(-22.1%) | -$72.57M(+5.2%) |
| Jun 2018 | - | -$35.46M(+45.9%) | -$68.96M(+24.2%) |
| Mar 2018 | - | -$24.30M(-264.1%) | -$55.54M(-27.0%) |
| Dec 2017 | -$76.06M(-43.9%) | $14.81M(-161.7%) | -$76.08M(-40.9%) |
| Sep 2017 | - | -$24.01M(+9.0%) | -$128.80M(-8.6%) |
| Jun 2017 | - | -$22.04M(-50.9%) | -$140.88M(-9.1%) |
| Mar 2017 | - | -$44.84M(+18.2%) | -$154.99M(+14.2%) |
| Dec 2016 | -$135.66M(+122.0%) | -$37.92M(+5.1%) | -$135.76M(+15.2%) |
| Sep 2016 | - | -$36.09M(-0.1%) | -$117.83M(+16.3%) |
| Jun 2016 | - | -$36.14M(+41.1%) | -$101.31M(+33.4%) |
| Mar 2016 | - | -$25.61M(+28.2%) | -$75.92M(+24.2%) |
| Dec 2015 | -$61.12M(+63.2%) | -$19.98M(+2.1%) | -$61.12M(+18.2%) |
| Sep 2015 | - | -$19.57M(+81.9%) | -$51.72M(+24.0%) |
| Jun 2015 | - | -$10.76M(-0.4%) | -$41.72M(+7.5%) |
| Mar 2015 | - | -$10.81M(+2.0%) | -$38.80M(+3.3%) |
| Dec 2014 | -$37.45M(+135.1%) | -$10.59M(+10.7%) | -$37.57M(+13.2%) |
| Sep 2014 | - | -$9.57M(+22.3%) | -$33.18M(+20.0%) |
| Jun 2014 | - | -$7.83M(-18.3%) | -$27.64M(+20.5%) |
| Mar 2014 | - | -$9.58M(+54.5%) | -$22.93M(+43.9%) |
| Dec 2013 | -$15.93M(+86.9%) | -$6.20M(+53.7%) | -$15.93M(+37.4%) |
| Sep 2013 | - | -$4.03M(+29.3%) | -$11.60M(+53.3%) |
| Jun 2013 | - | -$3.12M(+21.1%) | -$7.56M(+70.3%) |
| Mar 2013 | - | -$2.58M(+38.2%) | -$4.44M(+138.2%) |
| Dec 2012 | -$8.52M(-45.0%) | - | - |
| Dec 2012 | - | -$1.86M | -$1.86M |
| Dec 2011 | -$15.50M | - | - |
FAQ
- What is Akebia Therapeutics, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Akebia Therapeutics, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Akebia Therapeutics, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Akebia Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of AKBA is -$8.71M
What is the all time high annual EBITDA for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high annual EBITDA is -$4.23M
What is Akebia Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, AKBA annual EBITDA has changed by -$4.48M (-106.01%)
What is Akebia Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of AKBA is $14.40M
What is the all time high quarterly EBITDA for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high quarterly EBITDA is $57.39M
What is Akebia Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, AKBA quarterly EBITDA has changed by +$13.72M (+2002.92%)
What is Akebia Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of AKBA is $24.34M
What is the all time high TTM EBITDA for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high TTM EBITDA is $24.34M
What is Akebia Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, AKBA TTM EBITDA has changed by +$21.84M (+873.52%)